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Abstract
Purpose The subcutaneous implantable defibrillator (S-ICD) was developed to avoid complications related to transvenous leads.
A trade-off with the S-ICD is the inability to deliver antitachycardia pacing (ATP). Data is scarce about the recurrence and
characteristics of ventricular tachyarrhythmias (VTa) during a follow-up in survivors of out-of-hospital cardiac arrest due to
ventricular fibrillation (OHCA-VF). The aim of the study is to determine the characteristics of VTa triggering ICD therapy in
order to assess whether survivors of OHCA-VF are eligible candidates for the S-ICD.
Methods All OHCA-VF patients who received a transvenous ICD were identified, 378 patients, age 57 ± 14 years, predomi-
nantly male (76%) with ischemic heart disease (58%). Arrhythmic endpoints were appropriate ICD therapies for any ventricular
arrhythmia.
Results Over a median follow-up of 4.5 years, 690 VTa in 91 patients (24%) were terminated by ICD therapy; 70% of patients
had < 5 VTa with ICD therapy. VTa with cycle length ≤ 300 ms were mainly (82%) treated by shock, while 83% of VTa with
cycle length > 300 ms were treated by ATP. The presence of a remote myocardial infarction (OR 2.07; 95% CI 1.08–3.97) and
LVEF ≤ 0.35 (OR 2.09; 95% CI 1.09–4.00) were significantly associated with the occurrence of VTa with cycle length > 300 ms.
Conclusion S-ICD implantation may be reasonable in survivors of OHCA-VF who present without a remote myocardial infarc-
tion and LVEF > 35%.
Keywords Cardiac arrest . Ventricular fibrillation . Subcutaneous ICD . Appropriate shocks . Patient selection . Antitachycardia
pacing
1 Introduction
Placement of an implantable cardioverter-defibrillator (ICD) is
a class 1A indication for survivors of cardiac arrest due to
ventricular fibrillation (VF). These recommendations are based
on the results of randomized clinical trials [1–4]. ICD implan-
tation in the setting of secondary prevention has been labeled
as Bappropriate use^ in the recent Appropriate Use Criteria
Task Force report [5]. Despite the effectiveness of the ICD in
terminating life-threatening ventricular arrhythmias, contem-
porary transvenous ICD systems have been associated with
acute and chronic complications due to the use of transvenous
leads [6, 7]. Based on this, an entirely subcutaneous implant-
able defibrillator (S-ICD) has been developed as an alternative
to the transvenous ICD system [8]. The S-ICD-system holds
the promise of life-saving defibrillation [9–11]. However, a
trade-off with the S-ICD is the inability to deliver
antitachycardia pacing (ATP). The question arises Bwho are
candidates for the S-ICD system?^; one group is those patients
who are young and are, therefore, at greater lifelong risk of
complications from transvenous systems. Another opinion is
that the S-ICD should be limited to patients for primary pre-
vention of sudden death. Is secondary prevention of sudden
death a contra-indication for the S-ICD? Given the inability to
deliver ATP, the S-ICD is contra-indicated in secondary pre-
vention patients with a history of monomorphic ventricular
tachycardia (VT). But little is known about the recurrence
and characteristics of ventricular arrhythmias during follow-
up in survivors of cardiac arrest due to VF (OHCA-VF).
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The aim of the study is to determine characteristics of ven-
tricular arrhythmias triggering ICD therapy in order to assess
whether survivors of OHCA-VF are eligible candidates for the
S-ICD.
2 Methods
2.1 Study population
Patients for this retrospective observational cohort study were
obtained from the prospectively collected registry of all pa-
tients who underwent ICD implantation at the Erasmus
Medical Center, Rotterdam, The Netherlands. For the purpose
of the study, patients with ischemic or nonischemic heart dis-
ease who survived OHCA-VF were included. Patients with
age < 18 years or inherited arrhythmia disorders were exclud-
ed from analysis. The study period for inclusion was from
January 2000 to June 2015. The administrative censoring date
for analyses was December 2015 for all patients alive until
that date.
Data on baseline clinical characteristics, implantation pro-
cedures, and scheduled or unscheduled follow-up visits were
prospectively collected in the Erasmus MC ICD registry.
Information on clinical variables was acquired at the time of
ICD implantation. For all patients, renal function was assessed
by estimating the baseline glomerular filtration rate (eGFR)
using the abbreviated Modification of Diet in Renal Disease
(MDRD) Study equation [12]. Impaired renal function was
defined as an eGFR < 60 ml/min/1.73m2 according to practice
guidelines [13]. The elapsed time from most recent myocar-
dial infarction to ICD implantation was dichotomized at
18 months based on the results of the MADIT II study [14].
A remote myocardial infarction was defined as the time be-
tween most recent myocardial infarction and ICD implanta-
tion of ≥ 18 months. The programming of the VT zone of the
ICD was set to 330–350 ms and the VF zone was set to 250–
300 ms. Over the years, the programming of devices has
changed, current programming strategies apply higher rate
cutoffs and longer duration for arrhythmia detection. In order
to identify possible trends, we defined 3 groups according to
the implant year (1, 2000–2004; 2, 2005–2009; 3, 2010–
2015).
2.2 The follow-up and ICD therapy event analysis
The follow-up started at the time of ICD implantation.
Device interrogation was performed on regular visits
scheduled every 3- to 6-month basis, and after symptom-
atic events. At each visit, arrhythmic events with stored
electrograms (EGMs) were retrieved from the device’s
memory. Two investigators analyzed the stored EGMs with
therapy delivery to classify the arrhythmia and assess the
appropriateness of device classification and therapy.
Ventricular tachyarrhythmias were defined as events with
a sudden increase in rate combined with a change in ven-
tricular near-field and far-field EGM morphology from the
baseline rhythm. If an atrial EGM was present, the pres-
ence of atrioventricular dissociation (ventricular rate > atri-
al rate) was used to diagnose ventricular tachyarrhythmia.
The differentiation of polymorphic from monomorphic
ventricular tachyarrhythmias was based on regularity in
the rhythm and in the morphology of the near-field and
far-field EGMs. Polymorphic ventricular tachyarrhythmias
had irregularity in the rhythm and changing morphology in
near-field and far-field EGMs. Appropriate ICD therapy
was defined as ATP or shock delivered for a ventricular
tachyarrhythmia.
Survival status of patients was retrieved from the civil reg-
istry. As required by Dutch law, all deceased inhabitants must
be registered at the civil registry within 3 days. For analysis of
the endpoints, the maximum follow-up was set at 10 years.
For patients whose implant date was more than 10 years be-
fore December 2015, events occurring after 10 years were not
used in the analysis.
2.3 Statistical analysis
Normality of distribution as assessed using the Shapiro-Wilk
test. Continuous variables are presented as mean ± SD or as
median with 25th and 75th percentiles, where appropriate.
Data were compared by the ANOVA or Kruskal-Wallis test,
as appropriate. Categorical data are expressed as percentages
and compared with Fisher’s exact test. Cumulative mortality
and event rates of appropriate ICD therapy were calculated
according to the Kaplan-Meier method and were compared
with the log-rank test. Univariate predictors associated with
appropriate ICD therapy were included in a multivariate lo-
gistic regression model. Odds ratios (OR’s) are presented with
corresponding 95% confidence intervals (CI’s). Statistical
analysis was performed using STATA version 12 SE for
Windows (StataCorp, College Station, TX) and SPSS version
24 (IBM Corp., Somers, NY). Statistical significance was de-
fined as P < 0.05 (two-tailed).
3 Results
3.1 Study population
The study cohort consisted of 378 patients. The population
was predominantly male (76%) with a mean age of 57 ±
14 years. The majority of patients had ischemic heart disease
(58%) and the mean LVEF was 40 ± 16%, with 154 patients
(41%) having a LVEF ≤ 35%. Further baseline characteristics
of the study population are presented in Table 1. The median
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follow-up was 4.5 years (2.0 to 7.6 years), during which 91
patients (24%) received appropriate device therapy (ATP or
shock) and 66 patients (18%) died.
3.2 The first appropriate ICD intervention
The cumulative incidences of appropriate device therapy were
18%, 25%, and 34%, at 2, 4, and 10 years, respectively. As
shown in Fig. 1, the risk for appropriate ICD therapy was
highest during the first 2 years after implantation and persisted
during the long-term follow-up. The median interval to the
first any appropriate ICD intervention was 1.1 years (1.6–
6.0 years). The first appropriate ICD intervention was shock
delivery as initial therapy in 48 patients and ATP in 43 pa-
tients. The mean cycle length of shocked ventricular tachyar-
rhythmias was 231 ± 41 ms, and the mean cycle length of
ventricular tachyarrhythmias treated by ATP was 307 ±
34 ms (P < 0.001).
In Fig. 2, the temporal trend of appropriate ICD therapy by
the implant period is presented. At the 3-year follow-up, cu-
mulative appropriate ICD therapy is higher in patients
implanted before 2005 than those implanted later (39.7% ver-
sus 24.1% and 14.7%; both P’s < 0.05). The mean cycle
length of ventricular tachyarrhythmias triggering the first ap-
propriate ICD therapy was not different between the different
implant periods (P = 0.70).
3.3 Ventricular tachyarrhythmias triggering ICD
intervention
In total, 690 episodes with appropriate ICD intervention (91
patients) were adjudicated. The number of episodes ranged
from 1 to 95 per patient. The majority of patients (70%) ex-
perienced less than 5 episodes with appropriate ICD interven-
tions. Table 2 shows characteristics of the episodes with ap-
propriate ICD therapy. Four hundred ninety-five episodes for
which ATP was delivered as the first therapy were recorded in
59 patients (range 1 to 72 episodes per patient). Subsequent
shock delivery was necessary in 132 (27%) of these episodes
in 26 patients (range 1 to 70 episodes per patient). Shock as
initial therapy was delivered in 195 episodes (62 patients;
range 1 to 19 per patient).
Figure 3 presents the distribution of cycle lengths of ven-
tricular tachyarrhythmias for which ICD therapy was deliv-
ered. The mean cycle length of shocked arrhythmias was
shorter compared to those treated with ATP (229 ± 39 ms ver-
sus 326 ± 52 ms; P < 0.001). When considering a cutoff value
of 300 ms for cycle length, the majority of arrhythmias with
cycle length ≤ 300 ms (82%) were treated by shock, either as
initial therapy or after unsuccessful ATP. In contrast, arrhyth-
mias with cycle length > 300mswere mainly (83%) treated by
ATP only. The association between clinical covariates and
ventricular arrhythmias with cycle length > 300 ms in univar-
iate and multivariate logistic regression analyses is shown in
Table 3. The presence of a remote myocardial infarction (OR
2.08; 95% CI 1.08–3.97) and LVEF ≤ 0.35 (OR 2.09; 95% CI
1.09–4.00) were significantly associated with the occurrence
of ventricular tachyarrhythmias with cycle length > 300 ms
which are mainly terminated by ATP. When considering the
implant period, ventricular arrhythmias with cycle length >
300 ms were less likely to occur in patients implanted after
2010 (OR 0.29; 95% CI 0.12–0.69).
3.4 Mortality
During follow-up, 66 patients (18%) died. At 10-year follow-
up, the observed cumulative mortality was 35%. The median
interval from device implantation to death was 2.7 years (1.6–
6.0 years). In univariate analysis, no association between any
appropriate device therapy (ATP or shock) and mortality was
observed (P = 0.45). When considering appropriate ICD
shocks, a similar result was found (P = 0.41).
Table 1 Demographics and clinical characteristics at baseline
Total (n = 378)
Demographics
Age, y 57 ± 14
Male gender 286 (76%)
Clinical characteristics
Ischemic heart disease 218 (58%)
Myocardial infarction 171 (45%)
History of CABG 67 (18%)
History of PCI 120 (32%)
Dilated cardiomyopathy 49 (13%)
NYHA class > II 25 (7%)
Ejection fraction, % 40 ± 16
QRS duration, ms 110 (98–134)
Diabetes mellitus 50 (13%)
eGFR, ml/min/1.73m2 83 ± 27
eGFR < 60 ml/min/1.73m2 67 (18%)
Pharmacological therapy
Amiodarone 56 (15%)
Beta blocker 284 (75%)
Digoxin 35 (9%)
ACE inhibitor 259 (69%)
Diuretic 157 (42%)
Statin 204 (54%)
Continuous data are presented as mean ± SD or median and correspond-
ing 25th and 75th percentiles
ACE, angiotensin converting enzyme; eGFR, estimated glomerular filtra-
tion rate; NYHA, New York Heart Association
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4 Discussion
In the current study, we show the rate distribution of ventric-
ular tachyarrhythmias and type of delivered ICD therapy, in
patients who survived OHCA-VF. The main findings are (1)
the cumulative incidence of appropriate ICD therapy at
10 years was 34%, (2) the majority of patients (70%) experi-
enced less than 5 ventricular tachyarrhythmias treated with
ICD therapy, (3) ventricular tachyarrhythmias with cycle
length ≤ 300 ms are mainly terminated by shock, and (4) the
presence of LVEF ≤ 0.35 and a remote myocardial infarction
are associated with slower ventricular tachyarrhythmias (cycle
length > 300 ms).
Although prophylaxis of ICD therapy has been widely
studied, there is relatively little data on the outcome of patients
with a secondary prevention indication. The incidence of ap-
propriate ICD therapy in a secondary prevention population
has been studied in a few studies. Freedberg et al. [15] ob-
served appropriate ICD therapy in 62% of patients after the 2-
year follow-up. In the Leiden registry, cumulative incidences
of appropriate ICD therapy were 52% and 61%, at 5 and
10 years, respectively [16]. More recently, Schaer et al. [17]
reported a cumulative incidence of appropriate ICD therapy of
65% at 10 years. The incidence of appropriate ICD therapy in
our study (33.5% at 10 years) is lower compared to the previ-
ous studies. The higher incidences in previous studies can be
Fig. 2 Cumulative incidence of
the first ever appropriate ICD
therapy (ATP or shock) stratified
by 3 groups of date of ICD
implantation. Solid line,
implantation 2000–2004; long
dashed line, implantation 2005–
2009; short dashed line, implan-
tation 2010–2015
Fig. 1 Cumulative incidence of
the first ever appropriate ICD
therapy (ATP or shock)
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explained by the heterogeneous group of patients with both
VF and VT as index arrhythmia. A post hoc analysis of the
Antiarrhythmics Versus Implantable Defibrillators (AVID) tri-
al compared the incidence of ICD therapy according to the
index arrhythmia [18]. After the 3-year follow-up, patients
with VT as index arrhythmia were more likely to experience
appropriate ICD therapy than those with VF as index arrhyth-
mia (75.5% versus 47.4%). In a recent cohort analysis of 239
patients with a median follow-up of 7.8 years, Boule et al.
[19], patients presenting with VF were less likely to require
appropriate ICD therapy compared to those presenting with
VT (sub-hazard ratio 0.62). Patients who were implanted after
an aborted cardiac arrest due to VF have a lower risk of ap-
propriate ICD therapy during the follow-up compared to those
with VT as index arrhythmia.
Studies reporting on the type of ventricular arrhythmias
during follow-up in secondary prevention patients are scarce.
Post hoc analysis of the Pacing Fast VT Reduces Shock
ThErapies (PainFREE Rx II) trial and the Inhibition of
Unnecessary RV Pacing with AV Search Hysteresis in ICDs
(INTRINSIC RV) trial demonstrated that the rate distribution
of ventricular arrhythmias was similar between the primary
and secondary prevention patients [20, 21]. However, the ma-
jority of secondary prevention patients had VT as index ar-
rhythmia in both trials. In our study, only patients who sur-
vived OHCA-VFwere included to assess the eligibility for the
S-ICD. Patients with known recurrent monomorphic VT
thought to be amenable for ATP termination are considered
not eligible for the S-ICD. The presence of monomorphic VTs
is more common late after myocardial infarction due to reentry
around scar [22]. In the present study, slower ventricular ar-
rhythmias (rate < 200 bpm) were associated with the presence
of LVEF ≤ 35% and a remote myocardial infarction.
The armamentarium of devices that defibrillate in order to
prevent SCD has expanded in recent years. As a consequence,
ICDs have been used in patients with a variety of clinical
Table 2 Characteristics of
ventricular tachyarrhythmias by
therapy type
ATP only (n = 363) ATP + shock (n = 132) Shock only (n = 195)
No. of patients 51 26 62
Patients with ≥ 5 VTa 18 (29%) 4 (15%) 14 (23%)
VTa cycle length, ms 341 ± 48 285 ± 40 229 ± 39
VTa cycle length ≤ 300 ms 61 (17%) 86 (65%) 195 (100%)
Morphology of VTa
Monomorphic 363 (100%) 130 (98%) 129 (66%)
Polymorphic – 2 (2%) 66 (34%)
ATP, antitachycardia pacing; VTa, ventricular tachyarrhythmia
Fig. 3 Distribution of ventricular
tachyarrhythmias by initial rate
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needs, including those with documented monomorphic VTs,
survivors of OHCA-VF, patients with requirements for brady-
cardia pacing or cardiac resynchronization with a concomitant
indication for an ICD, and patients at increased risk for SCD.
Given the short- and long-term complications of ICDs, it is
important to select the right device carefully for each individ-
ual patient. In clinical practice, many physicians think that a
device without ATP to be inferior. However, the perceived
requirement of ATP must be balanced with the benefit of S-
ICD therapy whose risk of any VT is low for the first years
after implantation. Considering recurrent ventricular arrhyth-
mias in S-ICD patients, a recent analysis of the EFFORTLESS
registry demonstrated that only 2.2% of patients experienced
ICD therapy for more than 1 episode of monomorphic VT
[23]. In addition, only 0.5% of patients had the S-ICD re-
moved for conceived need for ATP. Taken all together, the
implantation of a S-ICD might be reasonable in survivors of
OHCA-VF with LVEF > 35% without the presence of a re-
mote myocardial infarction.
5 Limitations
Our study has several limitations. First, the study is a retro-
spective, single-center study. However, data in this ICD reg-
istry is prospectively collected. Another possible limitation is
that the risk of appropriate ICD therapy depends on ICD pro-
gramming. Over the years, programming of higher rate cutoffs
for detection and longer detection duration to reduce unnec-
essary ICD interventions has been recognized both in the pri-
mary and secondary preventions [24, 25]. We accounted for
this by defining 3 groups according to date of implant.
According to this, the reported overall incidence of appropri-
ate ICD therapy in the present study is probably overestimated
rather than underestimated. Last, the negative impact of
shocks on mortality has been consistently seen in trials with
the primary prevention patients. We found no association be-
tween shocks and mortality. However, our study was not de-
signed to evaluate the association between shocks and mortal-
ity. The impact of shocks on mortality in patients with a sec-
ondary prevention indication merits further investigation.
6 Conclusion
The findings of this study suggest that the implantation of the
S-ICD may be reasonable in survivors of OHCA-VF with
LVEF > 35% without a remote myocardial infarction.
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Table 3 Clinical covariates
associated with ventricular
arrhythmias (cycle length >
300 ms) in univariate and
multivariate analyses
Clinical covariates Univariate Multivariate
OR 95% CIs P value OR 95% CIs P value
Age (years) 1.01 0.99–1.03 0.42 – – –
Male gender 0.99 0.48–2.05 0.98 – – –
NYHA class > II 2.01 0.71–5.65 0.19 – – –
LVEF ≤ 0.35 2.37 1.26–4.49 0.008 2.09 1.09–4.00 0.03
Remote myocardial infarction 2.36 1.25–4.45 0.008 2.08 1.08–3.97 0.03
Implant period
2000–2004 (ref) – – – – – –
2005–2009 0.46 0.22–0.97 0.04 0.33 0.24–1.14 0.11
2010–2015 0.23 0.10–0.54 0.001 0.29 0.12–0.69 0.006
CIs, confidence intervals; OR, odds ratio; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association
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